These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 23839029)

  • 1. Comparison of a drug versus money and drug versus drug self-administration choice procedure with oxycodone and morphine in opioid addicts.
    Comer SD; Metz VE; Cooper ZD; Kowalczyk WJ; Jones JD; Sullivan MA; Manubay JM; Vosburg SK; Smith ME; Peyser D; Saccone PA
    Behav Pharmacol; 2013 Sep; 24(5-6):504-16. PubMed ID: 23839029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Buprenorphine/naloxone as a promising therapeutic option for opioid abusing patients with chronic pain: reduction of pain, opioid withdrawal symptoms, and abuse liability of oral oxycodone.
    Roux P; Sullivan MA; Cohen J; Fugon L; Jones JD; Vosburg SK; Cooper ZD; Manubay JM; Mogali S; Comer SD
    Pain; 2013 Aug; 154(8):1442-8. PubMed ID: 23707283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intranasal buprenorphine alone and in combination with naloxone: Abuse liability and reinforcing efficacy in physically dependent opioid abusers.
    Walsh SL; Nuzzo PA; Babalonis S; Casselton V; Lofwall MR
    Drug Alcohol Depend; 2016 May; 162():190-8. PubMed ID: 27012435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Within-subject comparison of the psychopharmacological profiles of oral oxycodone and oral morphine in non-drug-abusing volunteers.
    Zacny JP; Lichtor SA
    Psychopharmacology (Berl); 2008 Jan; 196(1):105-16. PubMed ID: 17899018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double blind, within subject comparison of spontaneous opioid withdrawal from buprenorphine versus morphine.
    Tompkins DA; Smith MT; Mintzer MZ; Campbell CM; Strain EC
    J Pharmacol Exp Ther; 2014 Feb; 348(2):217-26. PubMed ID: 24227768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of tradipitant, a selective NK1 antagonist, on response to oxycodone in humans.
    Coe MA; Lofwall MR; Vessels V; Nuzzo PA; Walsh SL
    Psychopharmacology (Berl); 2021 Jul; 238(7):1857-1866. PubMed ID: 33988725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intranasal abuse potential of an abuse-deterrent oxycodone formulation compared to oxycodone immediate release and placebo in nondependent, recreational opioid users.
    Setnik B; Schoedel K; Bartlett C; Dick C; Hakim N; Geoffroy P
    J Opioid Manag; 2017; 13(6):449-464. PubMed ID: 29308591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous oxycodone, hydrocodone, and morphine in recreational opioid users: abuse potential and relative potencies.
    Stoops WW; Hatton KW; Lofwall MR; Nuzzo PA; Walsh SL
    Psychopharmacology (Berl); 2010 Oct; 212(2):193-203. PubMed ID: 20665209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The subjective, reinforcing, and analgesic effects of oxycodone in patients with chronic, non-malignant pain who are maintained on sublingual buprenorphine/naloxone.
    Jones JD; Sullivan MA; Manubay J; Vosburg SK; Comer SD
    Neuropsychopharmacology; 2011 Jan; 36(2):411-22. PubMed ID: 20980992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Ibudilast on the Subjective, Reinforcing, and Analgesic Effects of Oxycodone in Recently Detoxified Adults with Opioid Dependence.
    Metz VE; Jones JD; Manubay J; Sullivan MA; Mogali S; Segoshi A; Madera G; Johnson KW; Comer SD
    Neuropsychopharmacology; 2017 Aug; 42(9):1825-1832. PubMed ID: 28393896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abuse liability of prescription opioids compared to heroin in morphine-maintained heroin abusers.
    Comer SD; Sullivan MA; Whittington RA; Vosburg SK; Kowalczyk WJ
    Neuropsychopharmacology; 2008 Apr; 33(5):1179-91. PubMed ID: 17581533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abuse liability of oxycodone as a function of pain and drug use history.
    Comer SD; Sullivan MA; Vosburg SK; Kowalczyk WJ; Houser J
    Drug Alcohol Depend; 2010 Jun; 109(1-3):130-8. PubMed ID: 20079977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opioid agonist doses for oxycodone and morphine dependence: Findings from a retrospective case series.
    Nielsen S; Bruno R; Degenhardt L; Demirkol A; Lintzeris N
    Drug Alcohol Rev; 2017 May; 36(3):311-316. PubMed ID: 27273511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analgesic efficacy and tolerability of intravenous morphine versus combined intravenous morphine and oxycodone in a 2-center, randomized, double-blind, pilot trial of patients with moderate to severe pain after total hip replacement.
    Joppich R; Richards P; Kelen R; Stern W; Zarghooni K; Otto C; Böhmer A; Petzke F; Treptau T; Lefering R; Bäthis H; Neugebauer E
    Clin Ther; 2012 Aug; 34(8):1751-60. PubMed ID: 22795613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of buprenorphine and naloxone in morphine-stabilized opioid addicts.
    Fudala PJ; Yu E; Macfadden W; Boardman C; Chiang CN
    Drug Alcohol Depend; 1998 Mar; 50(1):1-8. PubMed ID: 9589267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Within-subject comparison of the psychopharmacological profiles of oral hydrocodone and oxycodone combination products in non-drug-abusing volunteers.
    Zacny JP; Gutierrez S
    Drug Alcohol Depend; 2009 Apr; 101(1-2):107-14. PubMed ID: 19118954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Positive and negative subjective effects of extended-release oxymorphone versus controlled-release oxycodone in recreational opioid users.
    Schoedel KA; McMorn S; Chakraborty B; Potts SL; Zerbe K; Sellers EM
    J Opioid Manag; 2011; 7(3):179-92. PubMed ID: 21823549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conversion of chronic pain patients from full-opioid agonists to sublingual buprenorphine.
    Daitch J; Frey ME; Silver D; Mitnick C; Daitch D; Pergolizzi J
    Pain Physician; 2012 Jul; 15(3 Suppl):ES59-66. PubMed ID: 22786462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abuse liability and reinforcing efficacy of oral tramadol in humans.
    Babalonis S; Lofwall MR; Nuzzo PA; Siegel AJ; Walsh SL
    Drug Alcohol Depend; 2013 Apr; 129(1-2):116-24. PubMed ID: 23098678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.